Company
Evive Biotech is a global biologics company focused on oncology, inflammatory and metabolic diseases. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, we adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience.
Mission
Revolutionary remedies for a healthy and happy world.
Vision
Developing innovative medicines for patients worldwide.
Values
Entrepreneurial
Value-driven
Integrity
Validation
Excellence
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
The First Patient was Dosed in Phase 2 Clinical Trial of F-652 in Patients with ACLF
- 3 December 2021
PLOS ONE Article Details IL-22’s Critical Role in Mitigating ARDS
- 12 November 2021
Evive Biotech Announces the Grand Opening of EWING R&D Center in San Francisco Bay Area
- 3 November 2021
Evive Biotech Announces the Appointment of Mr. Denny Hou as VP, Global Medical Research
- 28 October 2021
Evive Biotech Announces the Appointment of Dr. Kaiming Sun as VP, Clinical Biomarker
- 26 October 2021
Evive Biotech Announces the Appointment of Dr. Simon Li as Executive VP, Chief Medical Officer
- 15 October 2021
